OST-664
Fibrosis
DiscoveryActive
Key Facts
About Oncostellae
Oncostellae is a Spanish biotechnology startup developing innovative, small-molecule therapeutics for oncology and inflammatory/autoimmune diseases. Its strategy centers on creating novel chemical scaffolds targeting clinically validated pathways, with a lead program, OST-122, demonstrating promising Phase 2a proof-of-concept in ulcerative colitis. The company operates a capital-efficient model, advancing programs to clinical proof-of-concept before out-licensing to pharmaceutical partners for late-stage development and commercialization.
View full company profileTherapeutic Areas
Other Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lead Fibrosis Program | Nosis Bio | Preclinical |
| Liver Fibrosis Assay | TissueVision | Preclinical |
| NBA-1901 | NB Health Laboratory | Preclinical |
| Undisclosed second mAb | NB Health Laboratory | Preclinical |